A Phase 1 interventional study of Liraglutide and Placebo in Obesity, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-26.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 41st largest by enrollment, is one of 12 that started in 2017, is one of 9 in phase 1, and was the 39th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 12 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
64 studies in Obesity by Pfizer: 13 open now, 19 under way, 12 of them phase 3. Of 43 finished, 11 (26%) have results posted.
Among the 64 studies in Obesity by Pfizer, this one is the 38th largest by enrollment of the 62 interventional ones that give a count, is the only one that started in 2017, is one of 30 in phase 1, and was the 24th registered.
Pfizer’s Obesity studies by the year they started, since 2004.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Pfizer’s 64 in Obesity:
This tab as a report to print or save as PDF → With an account.
This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liraglutide
Drug: Liraglutide
Placebo comparator
Other: Placebo
Liraglutide
Placebo
Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5
The mean energy intake was collected to assess the effect of liraglutide on food intake in non-diabetic, obese participants. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Mean energy intakes at Visit 4 was defined as the mean values of the measurements at Study Day 20 and 21. Same definition applies to Visit 5 (Study Day 41 and 42). Baseline was defined as the mean of Visit 3 (Study Day -1 and 0).
Time frame: Visit 3, Visit 4 and Visit 5
Number of Participants With Vital Signs Data Meeting Categorical Criteria
Absolute values and changes from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate (PR) were recorded in supine position. Vital signs categorical summarization criteria were 1), blood pressure: SBP greater than or equal to (\>=) 30 millimeters of mercury (mm Hg) change from baseline, SBP less than (\<) 90 mm Hg; DBP \>=20 mm Hg change from baseline, DBP \<50 mm Hg; 2), PR \<40 or greater than (\>) 120 beats per minute (bpm). Baseline was defined as pre-treatment measurement on Day 1.
Time frame: Baseline (Visit 3) up to Visit 6 (Study Day 53)
Number of Participants With Treatment-Emergent Adverse Events (All-Causality)
Adverse event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device, regardless of its causal relationship with study treatment. An AE is considered treatment-emergent relative to a given treatment if: the event occurs for the first time during the effective duration of treatment and was not seen prior to the start of treatment (for example, during the baseline or run-in period); or the event was seen prior to the start of treatment but increased in severity during treatment.
Time frame: Baseline (Visit 3) up to 31 days post last dose (75 days)
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG)
ECG categorical summarization criteria: 1) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): absolute value greater than or equal to (\>=) 300 msec, percent change \>=25% if baseline was greater than (\>) 200 msec, and \>=50% if baseline was less than or equal to (\<=) 200 msec; 2) QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): absolute value \>=200 msec, percent change \>=25% if baseline was 100 msec, and \>=50% if baseline was \<=100 msec; 3) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value \>450 to \<=480 msec, \>480 to \<=500 msec, \>500 msec, an increase from baseline \>30 to \<=60 msec or \>60 msec. Baseline was defined as pre-treatment measurement on Day -2.
Time frame: Baseline (Visit 3) up to Visit 6 (Study Day 53)
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Below parameters were evaluated:1), Hematology: hemoglobin (HGB), hematocrit, erythrocytes (absolute value/mean corpuscular volume/mean corpuscular HGB/mean corpuscular HGB concentration), platelets, leukocytes, lymphocytes, neutrophils, basophils, monocytes; 2), clinical chemistry: bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, amylase, triacylglycerol lipase; 3), urinalysis: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria.
Time frame: Baseline (Visit 3) up to Visit 6 (Study Day 53)
Change From Baseline in Mean 48-hour Energy Intake at Visits 4 and 5
Energy intake was measured over a period of 48 hours to assess day to day variability in food intake. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Baseline was defined as the 48 hour period at Visit 3 (Study Day -1 and 0).
Time frame: Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)
Change From Baseline in Appetite Score (Mean Rating Area Under Curve From Time 30 to 120 Minutes [AUC30-120min]) for Mean Lunch at Visits 4 and 5
Appetite, satiety, fullness, hunger, and prospective consumption were measured using a validated Visual Analog scale (VAS) questionnaire. VAS was an assessment in which participants place a vertical line across a validated 100 millimeter (mm) line with the example of "Not At All Full" and "Totally Full" at either end, scoring from 0 to 100. The overall appetite score was calculated as the average of the four individual scores \[satiety + fullness + (100 - prospective food consumption)+(100 - hunger)\] divided by 4. The VAS questionnaire was completed by the participant immediately prior to meal administration, and at 30, 60 and 120 minutes after start of the specified meals. Baseline of Mean Rating AUC30-120min was defined as the rating for mean lunch at Visit 3 (Study Day -1 and 0).
Time frame: Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)
Change From Baseline in Satiety, Fullness, Prospective Food Consumption and Hunger Scores (Mean Rating AUC30-120min) for Mean Lunch at Visits 4 and 5
Satiety, fullness, hunger, and prospective consumption were measured at the study site using a validated VAS questionnaire. The VAS measurement of the subcomponent scores were the same as that of the appetite score. Baseline of Mean Rating AUC30-120min was defined as the rating for mean lunch at Visit 3 (Study Day -1 and 0).The VAS was an assessment in which subjects place a vertical line across a validated 100 millimeter (mm) line to rank their response to various questions. The line was anchored by responses such as "Not At All Full" and "Totally Full" at either end. Scoring consisted of measuring the distance in mm of the vertical line from the response at the left end. The scores (total and subscale) ranged from 0 to 100. The lower values represent the better outcomes.The overall appetite score was calculated as the average of the 4 individual scores \[satiety+fullness+(100-prospective food consumption)+(100-hunger)\] divided by 4.
Time frame: Visit 3, Visit 4 (Study Day 20 and 21) and Visit 5 (Study Day 41 and 42)
Change From Baseline in Area Under the Plasma Concentration-Time Profile of Acetaminophen for 0-60 Minutes and 0-300 Minutes (AUC0-60min and AUC0-300min) After Acetaminophen Dose at Visits 4 and 5
A non investigational medicinal product (acetaminophen 1.5 gram \[g\]) was administered as a challenge agent for the assessment of gastric emptying. The blood sampling for determining acetaminophen concentrations was performed at 7 time points: prior to breakfast and at 30, 60, 90, 120, 180 and 300 minutes after intake of the acetaminophen with breakfast. Baseline was calculated at Visit 3 (Study Day -1).
Time frame: Prior to breakfast and at 30,60,90,120,180 and 300 minutes after intake of the acetaminophen with breakfast on Visit 3,Visit 4 (Study Day 20) and Visit 5 (Study Day 41)
| Milestone | Liraglutide | Placebo |
|---|---|---|
| Started | 32 | 29 |
| Received treatment | 32 | 28 |
| Completed | 28 | 26 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Death in the family | 0 | 2 |
| Withdrew: Randomized but not treated | 0 | 1 |
The mean energy intake was collected to assess the effect of liraglutide on food intake in non-diabetic, obese participants. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Mean energy intakes at Visit 4 was defined as the mean values of the measurements at Study Day 20 and 21. Same definition applies to Visit 5 (Study Day 41 and 42). Baseline was defined as the mean of Visit 3 (Study Day -1 and 0).
| kilocalories (kcal) | Liraglutide | Placebo |
|---|---|---|
| Visit 4 | -254.48 ± 160.67 | -19.93 ± 162.12 |
| Visit 5 | -278.78 ± 190.09 | -37.43 ± 164.49 |
Absolute values and changes from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate (PR) were recorded in supine position. Vital signs categorical summarization criteria were 1), blood pressure: SBP greater than or equal to (\>=) 30 millimeters of mercury (mm Hg) change from baseline, SBP less than (\<) 90 mm Hg; DBP \>=20 mm Hg change from baseline, DBP \<50 mm Hg; 2), PR \<40 or greater than (\>) 120 beats per minute (bpm). Baseline was defined as pre-treatment measurement on Day 1.
| Participants | Liraglutide | Placebo |
|---|---|---|
| Supine DBP <50 mmHg | 3 | 5 |
| Supine PR <40 bpm | 0 | 0 |
| Supine PR >120 bpm | 0 | 0 |
| Supine SBP <90 mmHg | 1 | 2 |
| Increase in supine DBP >=20 mmHg | 3 | 1 |
| Increase in supine SBP >=30 mmHg | 1 | 1 |
| Decrease in supine DBP >=20 mmHg | 3 | 9 |
| Decrease in supine SBP >=30 mmHg | 1 | 0 |
Adverse event (AE) was defined as any untoward medical occurrence in a study participant administered a product or medical device, regardless of its causal relationship with study treatment. An AE is considered treatment-emergent relative to a given treatment if: the event occurs for the first time during the effective duration of treatment and was not seen prior to the start of treatment (for example, during the baseline or run-in period); or the event was seen prior to the start of treatment but increased in severity during treatment.
| Participants | Liraglutide | Placebo |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (All-Causality) | 31 | 20 |
ECG categorical summarization criteria: 1) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): absolute value greater than or equal to (\>=) 300 msec, percent change \>=25% if baseline was greater than (\>) 200 msec, and \>=50% if baseline was less than or equal to (\<=) 200 msec; 2) QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): absolute value \>=200 msec, percent change \>=25% if baseline was 100 msec, and \>=50% if baseline was \<=100 msec; 3) QTcF interval (QT corrected for heart rate using Fridericia's formula): absolute value \>450 to \<=480 msec, \>480 to \<=500 msec, \>500 msec, an increase from baseline \>30 to \<=60 msec or \>60 msec. Baseline was defined as pre-treatment measurement on Day -2.
| Participants | Liraglutide | Placebo |
|---|---|---|
| PR interval >=300 milliseconds (msec) | 0 | 0 |
| QRS interval >=200 msec | 0 | 0 |
| QTcF >450 - <=480 msec | 2 | 2 |
| QTcF >480 - <=500 msec | 0 | 0 |
| QTcF >500 msec | 0 | 0 |
| PR interval percent increase >=25/50% | 0 | 0 |
| QRS interval percent increase >=25/50% | 0 | 0 |
| QTcF increase >30 - <=60 msec | 2 | 1 |
| QTcF increase >60 msec | 0 | 0 |
Below parameters were evaluated:1), Hematology: hemoglobin (HGB), hematocrit, erythrocytes (absolute value/mean corpuscular volume/mean corpuscular HGB/mean corpuscular HGB concentration), platelets, leukocytes, lymphocytes, neutrophils, basophils, monocytes; 2), clinical chemistry: bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, creatinine, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, sodium, potassium, chloride, calcium, bicarbonate, amylase, triacylglycerol lipase; 3), urinalysis: pH, urine glucose, ketones, urine protein, urine hemoglobin, urobilinogen, urine bilirubin, nitrite, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria.
| Participants | Liraglutide | Placebo |
|---|---|---|
| Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 32 | 26 |
Energy intake was measured over a period of 48 hours to assess day to day variability in food intake. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Baseline was defined as the 48 hour period at Visit 3 (Study Day -1 and 0).
| kcal | Liraglutide | Placebo |
|---|---|---|
| Visit 4 | -1058.8 ± 627.61 | -205.64 ± 608.51 |
| Visit 5 | -1152.5 ± 745.71 | -242.84 ± 681.37 |
Appetite, satiety, fullness, hunger, and prospective consumption were measured using a validated Visual Analog scale (VAS) questionnaire. VAS was an assessment in which participants place a vertical line across a validated 100 millimeter (mm) line with the example of "Not At All Full" and "Totally Full" at either end, scoring from 0 to 100. The overall appetite score was calculated as the average of the four individual scores \[satiety + fullness + (100 - prospective food consumption)+(100 - hunger)\] divided by 4. The VAS questionnaire was completed by the participant immediately prior to meal administration, and at 30, 60 and 120 minutes after start of the specified meals. Baseline of Mean Rating AUC30-120min was defined as the rating for mean lunch at Visit 3 (Study Day -1 and 0).
| units on a scale | Liraglutide | Placebo |
|---|---|---|
| Visit 4 | 4.52 ± 8.65 | -0.60 ± 9.22 |
| Visit 5 | 4.13 ± 9.99 | -0.99 ± 8.17 |
Satiety, fullness, hunger, and prospective consumption were measured at the study site using a validated VAS questionnaire. The VAS measurement of the subcomponent scores were the same as that of the appetite score. Baseline of Mean Rating AUC30-120min was defined as the rating for mean lunch at Visit 3 (Study Day -1 and 0).The VAS was an assessment in which subjects place a vertical line across a validated 100 millimeter (mm) line to rank their response to various questions. The line was anchored by responses such as "Not At All Full" and "Totally Full" at either end. Scoring consisted of measuring the distance in mm of the vertical line from the response at the left end. The scores (total and subscale) ranged from 0 to 100. The lower values represent the better outcomes.The overall appetite score was calculated as the average of the 4 individual scores \[satiety+fullness+(100-prospective food consumption)+(100-hunger)\] divided by 4.
| units on a scale | Liraglutide | Placebo |
|---|---|---|
| Satiety (Visit 4) | 3.94 ± 13.50 | -0.55 ± 10.52 |
| Satiety (Visit 5) | 4.51 ± 11.79 | 1.02 ± 9.26 |
| Fullness (Visit 4) | 4.04 ± 9.52 | 1.88 ± 10.85 |
| Fullness (Visit 5) | 2.40 ± 10.08 | 1.89 ± 9.17 |
| Prospective food consumption (Visit 4) | -7.74 ± 12.87 | 1.59 ± 12.38 |
| Prospective food consumption (Visit 5) | -6.18 ± 16.92 | 4.23 ± 14.46 |
| Hunger (Visit 4) | -3.71 ± 7.97 | 2.13 ± 10.88 |
| Hunger (Visit 5) | -3.41 ± 8.96 | 2.63 ± 13.00 |
A non investigational medicinal product (acetaminophen 1.5 gram \[g\]) was administered as a challenge agent for the assessment of gastric emptying. The blood sampling for determining acetaminophen concentrations was performed at 7 time points: prior to breakfast and at 30, 60, 90, 120, 180 and 300 minutes after intake of the acetaminophen with breakfast. Baseline was calculated at Visit 3 (Study Day -1).
| microgram*minute/milliliter (ug*min/mL) | Liraglutide | Placebo |
|---|---|---|
| AUC0-60min (Visit 4) | 18.30 ± 204.93 | -4.55 ± 262.11 |
| AUC0-60min (Visit 5) | 81.19 ± 166.47 | -8.28 ± 258.55 |
| AUC0-300min (Visit 4) | 197.79 ± 491.11 | -12.92 ± 489.50 |
| AUC0-300min (Visit 5) | 394.22 ± 401.62 | 47.31 ± 564.52 |
Collected over From Baseline (Visit 3, Study Day -1 and Day 0) to Day 73.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide | 0/32 (0%) | 0/32 (0%) | 30/32 (93.8%) |
| Placebo | 0/28 (0%) | 0/28 (0%) | 18/28 (64.3%) |
| Event | Liraglutide | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 15/32 | 1/28 |
| DiarrhoeaGastrointestinal disorders | 11/32 | 4/28 |
| HeadacheNervous system disorders | 11/32 | 3/28 |
| ConstipationGastrointestinal disorders | 9/32 | 3/28 |
| Decreased appetiteMetabolism and nutrition disorders | 8/32 | 2/28 |
| DyspepsiaGastrointestinal disorders | 7/32 | 2/28 |
| Injection site bruisingGeneral disorders | 7/32 | 4/28 |
| Abdominal pain upperGastrointestinal disorders | 6/32 | 1/28 |
| VomitingGastrointestinal disorders | 6/32 | 0/28 |
| DizzinessNervous system disorders | 6/32 | 1/28 |
All participants who met the criteria stated below were included in the full analysis set (FAS): completed baseline assessment of food intake; received at least one dose of randomized, blinded investigational product (IP); and completed at least one post baseline measurement (after taking randomized IP).
| Age, Continuous(years) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Mean | 43.0 ± 10.88 | 48.1 ± 12.63 | 45.4 ± 11.89 |
| Sex: Female, Male(Participants) | Liraglutide | Placebo | Total |
|---|---|---|---|
| Female | 22 | 16 | 38 |
| Male | 8 | 10 | 18 |
| Race/Ethnicity, Customized(Participants) | Liraglutide | Placebo | Total |
|---|---|---|---|
| White | 21 | 19 | 40 |
| Black or African American | 9 | 6 | 15 |
| Asian | 0 | 1 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Feb 2017 to primary completion in Jan 2018, 10 months.
Results were first posted in Jul 2019, 1 year 6 months after primary completion.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 10 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide